Elan may sell European concerns

PHARMACEUTICAL giant Elan says it is in talks on the sale of some of its European operations.

The company’s share price collapsed by 90% last year when serious flaws in its accounting techniques were exposed.

Since then the company has been forced to sell assets to cut its debt mountain which is still well over $2 billion. The group said the talks were directly aimed at its sales and marketing divisions.